Ryan Lin
Associate
Ryan Lin is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he focuses on intellectual property matters relating to biotechnology and life sciences.
Experience
Ryan Lin is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he focuses on intellectual property matters relating to biotechnology and life sciences.
Education
- J.D., University of San Diego School of Law, 2024
- Ph. D., Biological Chemistry, University of California, Irvine, 2012
- B.S., Molecular, Cellular, and Developmental Biology, University of California, Los Angeles, 2006
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., University of San Diego School of Law, 2024
- Ph. D., Biological Chemistry, University of California, Irvine, 2012
- B.S., Molecular, Cellular, and Developmental Biology, University of California, Los Angeles, 2006
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemical assays
- Biochemistry
- Biologics
- Cancer biology
- Cancer therapeutics
- Cell biology
- Cell therapy
- Cellular biology
- Genetics
- Metabolomics
- Molecular genetics
- PCR
Therapeutics and Drug Discovery
- CRISPR
- Drug delivery
- Gene editing
- Gene therapy
- Peptide therapeutics
Diagnostics and Medical Devices
- Biomedical engineering
- Diagnostics
Genomics and Data Analysis
- Functional genomics
- Next-generation sequencing
- rDNA
- Sequencing
- shRNA
- Single-cell sequencing
Miscellaneous
- Cancer
- COVID 19
- Engineered foods
Technical Fluency
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemical assays
- Biochemistry
- Biologics
- Cancer biology
- Cancer therapeutics
- Cell biology
- Cell therapy
- Cellular biology
- Genetics
- Metabolomics
- Molecular genetics
- PCR
Therapeutics and Drug Discovery
- CRISPR
- Drug delivery
- Gene editing
- Gene therapy
- Peptide therapeutics
Diagnostics and Medical Devices
- Biomedical engineering
- Diagnostics
Genomics and Data Analysis
- Functional genomics
- Next-generation sequencing
- rDNA
- Sequencing
- shRNA
- Single-cell sequencing
Miscellaneous
- Cancer
- COVID 19
- Engineered foods
Focus Areas
Recent Insights
Client Highlights
Firm Advises Mirador on Patent Matters Related to $250 Million Series B
On January 12, 2026, Mirador Therapeutics, Inc., a clinical-stage precision medicine company developing next-generation therapies for immune-mediated inflammatory and fibrotic diseases, announced it has closed a $250 million Series B financing, bringing total capital raised to more than $650 million since the company launched in March 2024. The proceeds enable Mirador to deliver proof-of-concept across all current programs and support the development of additional pipeline candidates. Wilson Sonsini Goodrich & Rosati has advised Mirador on patent matters since the company’s inception, and counseled Mirador on patent matters related to this latest transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Link Cell Therapies on Strategic Collaboration with Johnson & Johnson
On January 9, 2026, Link Cell Therapies, an oncology cell therapy company, announced a strategic collaboration with Johnson & Johnson to develop novel logic-gated LINK CAR T therapies. The collaboration follows the recently announced Series A financing in Link that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc., which included participation of additional strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the matter.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.